Search

Your search keyword '"Paterno, Giovangiacinto"' showing total 145 results

Search Constraints

Start Over You searched for: Author "Paterno, Giovangiacinto" Remove constraint Author: "Paterno, Giovangiacinto"
145 results on '"Paterno, Giovangiacinto"'

Search Results

2. Evolution of transcriptomic profiles in relapsed inv(16) acute myeloid leukemia

4. The ISTH DIC-score predicts early mortality in patients with non-promyelocitic acute myeloid leukemia

6. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol

9. Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells

11. Acute leukemia diagnosis during the COVID-19 pandemic

12. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope

14. FEVER OF UNKNOWN ORIGIN AND MULTIDRUG-RESISTANT ORGANISMS COLONIZATION IN AML PATIENTS.

16. Clinical features and prognostic factors of Magnusiomyces (Saprochaete) infections in haematology. A multicentre study of SEIFEM/Fungiscope

17. Predictors of Early Thrombotic Events in Adult Patients with Acute Myeloid Leukemia: A Real-World Experience

18. Real Life Feasibility of a Combined Clinical and Biological Fitness Assessment in Patients with Acute Myeloid Leukemia

20. In BCR-ABL1 Positive B-Cell Acute Lymphoblastic Leukemia, Steroid Therapy Induces Hypofibrinogenemia

21. Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial

22. Occult central nervous system involvement guides therapeutic choices in blastic plasmacytoid dendritic cell neoplasms

23. Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia

24. Therapy-related Myeloid Neoplasms: Considerations for Patients' Clinical Evaluation.

26. CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia

27. Results of the 6-Year Follow-up of the Gimema AML1310 Trial: A Risk-Adapted, MRD-Directed Therapy for Young Adults with Newly Diagnosed Acute Myeloid Leukemia

29. COVID-19 infection in adult patients with hematological malignancies:a European Hematology Association Survey (EPICOVIDEHA)

30. Use of Measurable Residual Disease to Evolve Transplant Policy in Acute Myeloid Leukemia: A 20-Year Monocentric Observation

31. CD34 + CD38-CLL1+ leukemic stem cells persistence measured by multiparametric flow cytometry is a biomarker of poor prognosis in adult patients with acute myeloid leukemia.

32. Validation of ELN2017 Risk Stratification in a Post-Hoc Analysis of the Prospective Biomarker-Based Gimema AML1310 Protocol

33. Clinical Relevance of- Limit of Detection (LOD) - Limit of Quantification (LOQ) - Based Flow Cytometry Approach for Measurable Residual Disease (MRD) Assessment in Acute Myeloid Leukemia (AML)

36. Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network

37. Pneumocystis jirovecii pneumonia in patients with previously untreated acute myeloid leukaemia.

38. Diagnostic Performance and Safety of Bronchoalveolar Lavage in Thrombocytopenic Haematological Patients for Invasive Fungal Infections Diagnosis: A Monocentric, Retrospective Experience

39. Multiparametric Flow-Cytometry Is a Reliable Tool for Measurable Residual Disease Assessment and Risk-Stratification of FLT3-Mutated AML Patients

40. Mutational Profile of Leukemic Stem Cells in FLT3-ITD Mutated AML

41. Validation of SIE, Sies, GITMO Operational Criteria for the Definition of Fitness in Elderly Patients Affected with Acute Myeloid Leukemia: A Six-Years Retrospective Real-Life Experience

42. Leukemic Stem Cells Persistence Measured By Multiparametric Flow Cytometry Is a Biomarker of Poor Prognosis in Adult Patients with Acute Myeloid Leukemia

43. DIAGNOSTIC PERFORMANCE AND SAFETY OF BRONCHOALVEOLAR LAVAGE IN THROMBOCYTOPENIC HAEMATOLOGICAL PATIENTS FOR ASPERGILLOSIS DIAGNOSIS: A MONOCENTRIC, RETROSPECTIVE EXPERIENCE.

45. Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome

46. Pattern of Central Nervous System (CNS) Involvement in Adult Acute Myeloid Leukemia (AML) and Its Impact on Outcome

47. Intravenous Administration of Rituximab in the Treatment of Primary Cutaneous B-Cell Lymphomas (PCBCLs): A Retrospective Study

48. Characterization of FLT3-ITDmut acute myeloid leukemia: molecular profiling of leukemic precursor cells.

49. ELN2017 risk stratification improves outcome prediction when applied to the prospective, GIMEMA AML1310 protocol. ELN 2017 risk to guide treatment strategy in AML

50. ELN2017 risk stratification improves outcome prediction when applied to the prospective GIMEMA AML1310 protocol

Catalog

Books, media, physical & digital resources